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 College oAbstract Background: Fractional excretion of sodium (FENa) is used to differentiate renal from
prerenal azotemia. However, many drugs and medical conditions affect the sodium (Na+) handling
in the kidney. But the fractional excretion of urea (FEurea) is dependent on passive forces and is less
inﬂuenced by the diuretic therapy.
Objective: Comparison between FENa and FEurea in differentiating renal from prerenal azote-
mia in circulatory shock, and the effect of diuretics on their handling.
Methods: Both FENa and FEurea were measured in 40 patients (pts) with AKI complicating cir-
culatory shock. The pts were divided into 26 pts with prerenal (group-1) and 14 pts with renal azo-
temia (group-2). Group-1 was subdivided into 12 pts who did not receive diuretics 24 h before the
sampling process (group-1a) and 14 pts who received diuretics (group-1b).
Results: Compared to patients with renal azotemia (group-2), those with prerenal azotemia
(group-1) showed signiﬁcantly lower FENa (0.99 ± 0.66 and 2.57 ± 1.73, P< 0.05) respectively,
and signiﬁcantly lower FEurea (29.7 ± 7.6 and 43.7 ± 15.4, P< 0.001) respectively. For differen-
tiating renal from prerenal azotemia, compared to FENa, FEurea showed better sensitivity (78.1%
vs. 71.4%) and speciﬁcity (88.5% vs. 69.4%) respectively. Moreover, FEurea was not signiﬁcantly
affected by the use of diuretics; sensitivity (78% vs. 78%) and speciﬁcity (92% vs. 88%) respec-
tively, compared to pts who did not receive diuretics. On the other hand, compared to pts who
did not receive diuretics, the use of diuretics signiﬁcantly affected FENa; sensitivity (64% vs.
71%) and speciﬁcity (58% vs. 70%) respectively.1604228.
ail.com, hossam_sherif@cu.
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70 A.R. Yassin et al.Conclusions: FEurea is more sensitive, speciﬁc and less affected by the use of diuretics than
FENa in differentiating renal from prerenal azotemia in patients with AKI complicating circulatory
shock.
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The incidence of acute renal injury (AKI) in ICU is  5%. The
mortality rate increases up to 50% if AKI is a part of multiple
organ dysfunction syndrome [1,2]. Prerenal azotemia is
responsible for 30–40% of cases of oliguria in ICU; a situation
which can be usually reverted by correcting the underlying dis-
order, but prolonged or severe prerenal azotemia may proceed
to oliguric renal azotemia [2].
The outcome of patients with acute renal azotemia differs
signiﬁcantly from those with prerenal azotemia; the latter re-
ﬂects the physiological hemodynamic regulatory mechanisms
of conservation of water and electrolytes in response to hypo-
volemia and decreased glomerular ﬁltration rate (GFR) [1–3].
Early detection of renal and excluding prerenal azotemia
improve outcome [4]. Relying solely on the patient’s response
to ﬂuid challenge in order to differentiate prerenal azotemia
from renal azotemia, may lead to massive ﬂuid overload in
the latter [4,5].
Many laboratory tools have been used for differentiating re-
nal from prerenal azotemia including blood urea/serum creati-
nine ratio, urine analysis (granular casts in patients with renal
azotemia), urine osmolarity and speciﬁc gravity, urinary so-
dium level, urinary to plasma creatinine ratio (U/P Cr). How-
ever; all of them lack reasonable sensitivity and speciﬁcity [4–6].
One of these laboratory tools is the fractional excretion of
sodium (FENa) which showed a reasonable sensitivity and
speciﬁcity. FENa is the percentage of Na+ ﬁltered by the kid-
ney which is not reabsorbed and excreted in the urine. It de-
pends upon the fact that in the state of decreased renal
blood ﬂow, as in hypovolemia, there is enhanced reabsorption
of Na+ from renal tubules, making the fraction of the ﬁltered
Na+ that is excreted in urine less than normal which means
lower FENa in prerenal azotemia [4,5,7].
But unfortunately FENa (despite a simple lab tool) is af-
fected by many drugs and medical conditions. Drugs that in-
crease Na+ excretion in urine as diuretics and dopamine [8]
lead to false increase in FENa, and drugs that decrease Na+
excretion as norepinephrine lead to false decrease in FENa
[8,9]. Because 70% of ICU pts with AKI receive diuretic ther-
apy, and many patients with circulatory shock receive dopa-
mine and norepinephrine, the results of FENa are not
justiﬁed in such conditions [7]. Moreover, lactic acidosis that
occurs with circulatory shock may result in natriuresis and
may falsely increase FENa as well [10].
Solutes other than Na+, including urea, have been sug-
gested to improve the diagnostic ability in the above mentioned
clinical situations instead of FENa [7]. The fractional excretion
of urea (FEurea) is mainly dependent on passive forces in the
kidney and so is less inﬂuenced by the diuretic therapy [7].
The purpose of this study was to compare FENa and FEu-
rea in differentiating renal from prerenal azotemia, and to de-
tect the effect of diuretics on their handling. Few studies havespeciﬁcally addressed this issue, but never in patients with AKI
complicating circulatory shock.
Methods
This prospective study was conducted on 40 Egyptian patients
with AKI complicating circulatory shock admitted to the gen-
eral ICU of Al Fayoum University Hospital, from July 2011 to
July 2012. Consents were taken from all of them according to
the local ethics committee approval.
The patients were divided into two groups:
(1) Group-1: Included 26 patients; mean age 60.0 ± 15.15
(21–88) years (10 males) that had acute prerenal azote-
mia, and was subdivided into:
– Group-1a: Included 12 patients who did not receive
diuretics in the last 24 h before taking the urine and
blood samples.
– Group-1b: Included 14 patients who received diuret-
ics, in the last 24 h before taking the urine and blo-
od samples.(2) Group 2: Included 14 patients; mean age 56.29 ± 19.5
(23–92) years (18 males) that had acute renal azotemia.
Regarding age and sex, groups-1 and 2 were comparable.
Inclusion criteria
All patients presented with AKI complicating circulatory
shock during their stay in the ICU:
(1) Circulatory shock was diagnosed according to the
Empiric Criteria [11], which requires 4 out of the
following: Ill appearing or altered mental status.
 Heart rate > 100 beat/min.
 Respiratory rate > 22/min, or paCO2 < 32 mmHg.
 Arterial hypotension (systolic blood pressur-
e 6 90 mmHg, decrease in systolic blood pressure b-
y 40 mmHg from baseline or mean arterial blood
pressure 6 70 mmHg), for >20 min duration.
 Urine output < 0.5 mL/kg/h.
 Arterial base deﬁcit < 5 mEq/L, or lactic acidosis
(>2 mmol/L)(2) Acute kidney injury was diagnosed according to the
RIFLE-criteria (Risk, Injury, Failure, Loss and End-
stage Kidney) in oliguric patients [12]: (Table 1)
(3) Prerenal azotemia diagnosis was settled whenP6 of the
following criteria was found [10]:
 History: Volume depletion, congestive heart failure,
severe liver disease or other edematous states and a-
naphylaxis favor prerenal azotemia, while exposure
to exogenous toxins such as medications and recent
Table 1 RIFLE-criteria for diagnosing acute kidney injury.
Class Glomerular ﬁltration rate criteria Urine output criteria
Risk Serum creatinine · 1.5 <0.5 mL/kg/h for 6 h
Injury Serum creatinine · 2 <0.5 mL/kg/h for 12 h
Failure Serum creatinine · 3, or P4 mg/mL
with an acute rise >0.5 mg/mL
<0.3 mL/kg/h for 24 h,
or anuriaP 12 h
Loss Persistent acute renal failure
=complete loss of kidney function >4 weeks
End-stage kidney disease End-stage kidney disease >3 months
The serum creatinine increase is measured from its baseline value.
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nous toxins as in the case of myoglobinuria would
favor acute tubular necrosis
 Physical examination: Loss of skin elasticity and skin
turger in dehydrated patients, orthostatic changes in
heart rate, presence of ascites or pedal edema sug-
gests prerenal state.
 Response to ﬂuid challenge: Favors prerenal state [7].
 Urine analysis: No abnormalities or hyaline and ﬁne
granular casts in prerenal states, while presence of
muddy brown granular casts and renal tubular epi-
thelial cells or casts indicates acute renal failure [13].
 Urine speciﬁc gravity 6 1010 favors acute renal fail-
ure, while >1018 favors prerenal state.
 Urinary to plasma creatinine ratio (U/P Cr): If >20
is consistent with prerenal while levels <15 suggest
acute tubular necrosis.
 Blood urea/serum creatinine ratio:Would favor prere-
nal if >40 and acute renal failure if <40.
 Urinary sodium (UNa): If <15 mEq/L favors prere-
nal azotemia, while >20 mEq/L is consistent with
acute tubular necrosis.(4) Acute renal failure diagnosis was settled when <6 of the
previously mentioned criteria were present [10].
Exclusion criteria
 Chronic kidney disease.




 Osmotic diuresis as in usage of mannitol or acetazolamide
[7].
All patients were subjected to the following:
(1) Full history and clinical evaluation including the routine
ICU monitoring; ﬂuid balance sheet and hourly urine
output measurement.
(2) Routine renal function tests: Blood urea, serum creatinine, and Na+ and K+
levels.
 Blood urea/serum creatinine ratio.
 Urinary/serum creatinine ratio.
 Urinary Na+ level.
 Urine analysis. Urine speciﬁc gravity.
 Albumin/creatinine ratio or 24 h proteins in urine
were used to exclude diabetic nephropathy [6].(3) All patients had subjected to abdominal ultrasound to
exclude any chronic kidney disease or obstructive
nephropathy.
(4) Fractional excretion of sodium and fractional excretion
of urea
 FENa was calculated as [7]:FENa ¼ ½ðurinary sodium=plasma sodiumÞ=
ðurinary creatinine=plasma creatinineÞ  100 FEurea nitrogen was calculated as [7]:
FEureanitrogen¼½ðurinaryureanitrogen=bloodureanitrogenÞ=
ðurinecreatinine=plasmacreatinineÞ100




– Serum or heparinized plasma (except ammonium
heparin).
– Urine was diluted at 1/20 to 1/50 with distilled water
before analysis.
Storage:
– Serum and plasma are stable up to 24 h at room tem-
perature, for one week at 4 C. Frozen between 15
and 20 C, these samples are stable for at least 2–
3 months.
– Urine samples are stable up to 4 days if stored at 4–
8 C. Urines could be preserved with thymol to av-
oid bacterial action or by maintaining the pH below
4.
 Blood and urine chemistries and electrolytes were per-
formed on a Beckman automated analyzer (Beckman
Instruments, Fullerton, CA, USA). (SEPPIM ELITech
Group Company, European manufacturer of clinical chem-
istry diagnostic kits.)
(5) According to the medical situation and the cause of the
circulatory shock, all patients continued their medica-
tions including the vasopressor drugs during their enroll-
ment in the study.
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The collected data were organized, tabulated and statistically
analyzed using Statistical Package for Social Sciences (SPSS
Inc., USA) version 15.0. For quantitative data, the
means ± standard deviations (SD) were calculated. The inde-
pendent t-test and one-way ANOVA were used to test the sta-
tistical differences between groups. For qualitative data, the
number and percent distribution were calculated, chi square
(v2) was used as a test of signiﬁcance. Pearson’s and Spear-
man’s correlations were used to determine the relation between
FENa and FEurea with variables of the study when applicable.
ROC-curve was used to determine the cut-off point at which
highest sensitivity and speciﬁcity of FENa, FEurea and other
variables were differentiated between prerenal and renal fail-
ures. P-values 6 0.05 were considered statistically signiﬁcant
while 60.001 were considered highly statistically signiﬁcant.
Results
The patients who suffered from renal azotemia (group-2) sig-
niﬁcantly needed the mechanical ventilation and the renalTable 2 The demographic and clinical data.
Group-1 (prerenal)
MAP (mmHg) 38.4 ± 9.1 (25–58)
Heart rate (beat/min) 112 ± 22 (52–168)
Temperature (C) 36.9 ± 0.8 (35.5–40.2)
Respiratory rate (breath/min) 22 ± 11 (10–44)
Hypertension (n) 13 (50%)
Diabetes mellitus (n) 10 (38.5%)
Diuretics (n) 12 (46.2%)
Mechanical ventilation (n) 7 (27%)
Renal replacement therapy (n) 3 (11.5%)
Dopamine (n) 18 (69.2%)
Dobutamine (n) 14 (53.8%)
Noradrenaline (n) 13 (50%)
ICU stay (days) 8.0 ± 4.6 (2–15)
Mortality (n) 5 (19.2%)
NS: Non-signiﬁcant; MAP: Mean arterial blood pressure.
Table 3 The routine lab results.
Group-1 (prerenal)
Hemoglobin (mg/mL) 9.9 ± 2.1 (6.1–15.6)
WBC · 1000 (cell/cm3) 17,2 ± 4,5 (2,6–27,1)
Platelets · 1000 (n/cm3) 275 ± 70 (90–412)
AST (mg/mL) 89 ± 48 (27–353)
ALT (mg/mL) 82 ± 33 (22–312)
PT (seconds) 17.2 ± 4.2 (12.5–35)
PC (%) 72.2 ± 17 (34–97)
INR (ratio) 1.6 ± 1.1 (1.1–4.2)
Albumin (mg/mL) 2.9±.6 (1.7–5.2)
Total bilirubin (mg/mL) 1.4 ± 0.5 (0.6–6.1)
pH 7.25 ± 0.15 (6.92–7.31)
paO2 (on room air) (mmHg) 64 ± 14 (38–115)
paO2 (on MV) (mmHg) 109 ± 33 (45–350)
paCO2 (mmHg) 34.2 ± 12.5 (12.4–66.3)
HCO3 (mmol/L) 12 ± 6.1 (3.6–16.1)
NS: Non-signiﬁcant; WBC: White blood cell; AST: Aspartate transami
thrombin concentration; INR: International normalized ratio.replacement therapy than the patients with prerenal azotemia
(group-1). Furthermore, the mortality rate was signiﬁcantly
higher in group-2 (Table 2). But, the number of patients who
needed vasopressor drugs in their medication in both groups
was comparable (Table 2).
The results of the routine lab parameters were comparable
in both groups (Table 3).
Compared to group-2, the values of blood urea/serum cre-
atinine ratio, the urinary creatinine/plasma creatinine ratio
and the total urine output in the 1st 24 h were signiﬁcantly
higher, and the serum creatinine was signiﬁcantly lower in
group-1. On the other hand, the values of blood urea, serum
Na+ and urine Na+ in both groups were comparable (Fig. 1).
Compared to group-2 (renal patients), both FENa and
FEurea values of group-1 were signiﬁcantly lower (Fig. 2).
Using one-way ANOVA test, both FENa and EFurea
showed signiﬁcantly incremental values with higher RIFLE-
criteria from mild AKI (RIFLE-R), moderate AKI (RIFLE-
I) to severe AKI (RIFLE-F) class (Table 4).
Weak correlations could be detected between the serum cre-
atinine and both FENa and FEurea values (r= 0.36,
P< 0.05 and r= 0.37, P< 0.05) respectively, but goodGroup-2 (renal) P value
39 ± 8.2 (30–58) NS
122 ± 27 (46–176) NS
37.0 ± 0.6 (35.6–40.4) NS









7.4 ± 3.6 (2–16) NS
7 (50%) <0.05
Group-2 (renal) P value
11.2 ± 2.8 (5.6–17.3) NS
15,5 ± 3,2 (3,2–32,1) NS
264 ± 75 (65–392) NS
109 ± 77 (31–342) NS
86 ± 16 (26–317) NS
18.4 ± 3.1(12.6–41) NS
69.2 ± 22 (28–96) NS
2.1 ± 0.8 (1.1–4.8) NS
2.5 ± 0.4 (1.8–4.9) NS
1.4 ± 0.6 (0.5–7.1) NS
7.27 ± 0.22 (6.88–7.28) NS
59 ± 11 (39–122) NS
97 ± 32 (55–275) NS
29.1 ± 11.7 (14.6–80.1) NS
11 ± 5.5 (5.1–15.2) NS
nase; ALT: Alanine transaminase; PT: Prothrombin time; PC: Pro-
Figure 1 The renal function tests: Panel (A) Blood urea, (B) Serum creatinine, (C) Blood urea/serum creatinine ratio, (D) Urinary
creatinine/plasma creatinine, (E) Na+ in urine and (F) Urine output in 1st 24 h.
Figure 2 Comparison between prerenal (group-1) and renal (group-2) azotemia using FENa (panel A) and FEurea (panel B).
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Table 4 Effect of increased severity of AKI on FENa and
FEurea values using one-way ANOVA.
FENa (%) FEurea (%)
RIFLE-R 1.1 ± 0.3 31.4 ± 2.3
RIFLE- I 1.3 ± 0.5 35.4 ± 3.6
RIFLE-F 2.3 ± 0.4 41.4 ± 5.6
P value <0.05 <0.05
AKI: Acute kidney injury; RIFLE: Risk, Injury, Failure, Loss and
End-stage Kidney; R: Risk; I: Injury; F: Failure.
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ues (r= 57, P< 0.0010 (Fig. 3).
Compared to FENa, on using FEurea as a predictor in dif-
ferentiating renal from prerenal azotemia in all patients, higher
sensitivity (78.6%), speciﬁcity (88.5%) and overall accuracy
(85%) could be detected (Fig. 4A), than FENa; sensitivityFigure 3 Regression plot with Passing and Bablok ﬁt for: Panel (A) S
FENa vs. FEurea. The correlations were good. (––) Trendline, (—) Id(71.4%), speciﬁcity (69.4%) and overall accuracy (67.5%)
(Fig. 4B).
For patients who received diuretics, FEurea as a predictor
also could differentiate renal from prerenal azotemia (group-
1b)with higher sensitivity (78.4%), speciﬁcity (92.1%) and over-
all accuracy (85.7%) (Fig. 4C), than FENa; sensitivity (64.3%),
speciﬁcity (58.4%) and overall accuracy (59.4%) (Fig. 4D).
As a predictor of differentiation, the cutoff value of FEurea
was 34.12% (P< 0.001) and the cutoff value of FENa was
1.1% (P< 0.05).
Discussion
Fractional excretion of sodium (FENa) has been routinely
used for differentiating renal from prerenal azotemia [14].
However, the values of FENa are usually affected by the com-
monly used medications as diuretics, dopamine and norepi-
nephrine, and also by some clinical conditions aserum creatinine vs. FENa, (B) Serum creatinine vs. FEurea and (C)
entity line and (. . .) Passing and Bablok ﬁt lines.
Figure 4 ROC curves of (A) FEurea to differentiate renal (group-2) from prerenal azotemia (group-1), (B) FENa to differentiate renal
(group-2) from prerenal azotemia (group-1), (C) FEurea to differentiate renal (group-2) from prerenal azotemia in patients using diuretics
(group-1b) and (D) FENa to differentiate renal (group-2) from prerenal azotemia in patients using diuretics (group-1b).
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ent causes of metabolic acidosis [14]. On the contrary, the frac-
tional excretion of urea (FEurea) is suggested to be used
instead of FENa with better reliability to differentiate between
prerenal from renal azotemia, as its values are not affected by
the same drugs or medical conditions [1].
In our study we performed a prospective observation in a
general ICU on patients with acute kidney injury (AKI) com-
plicating circulatory shock, to explore the difference between
using both FENa and FEurea in differentiating renal from pre-
renal azotemia, and up to our knowledge this is the ﬁrst time to
perform such a comparison in patients with AKI complicating
circulatory shock in which 68% of them needed dopamine and
norepinephrine together in their ICU medication, making the
identiﬁcation of the effect of each drug alone on FENa and
FEurea statistically difﬁcult.In this study, we used the RIFLE-criteria to classify our pa-
tients with AKI into mild renal affection (RIFLE-R), moder-
ate renal affection (RIFLE-I) and severe renal affection
(RIFLE-F). We had detected signiﬁcantly incremental values
of both FENa and FEurea with the higher class of the RI-
FLE-criteria, and to our knowledge, it is the ﬁrst time to com-
pare FENa and FEurea versus the RIFLE-criteria.
Our study showed a fair correlation between the routine
serum creatinine marker and both FENa (r= 0.36,
P< 0.05), and FEurea (r= 0.37, P< 0.05), respectively.
The poor correlations can be explained by the serum creatinine
increase in both renal and prerenal azotemia, while FENa and
FEurea increase in renal azotemia and decrease in prerenal
azotemia [7]. These ﬁndings agree with the Carvounis study,
in which there were fair correlations between serum creatinine
and both FENa and FEurea [7].
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and FEurea in patients with renal azotemia than those with
prerenal azotemia (P< 0.05 and P< 0.001, respectively).
These also agree with Carvounis et al., who studied 102 pa-
tients with AKI; 76% with prerenal azotemia showed signiﬁ-
cantly lower FENa and lower FEurea values (P< 0.001),
while 24% of patients with renal azotemia showed signiﬁcantly
higher FENa and higher FEurea values (P< 0.001) [7].
It is important to mention here that good correlation could
be detected between FENa and FEurea (r= 0.67, P< 0.05) in
our study. This ﬁnding supports the trend of combining both
FENa and FEurea in one panel; ‘‘the panel of fractional excre-
tion of solutes’’ that includes FENa and FEurea which can
provide the most important insight into the differentiation be-
tween renal and prerenal azotemia in various clinical states as
suggested by Diskin [15]. However, our study showed that
FEurea had better sensitivity (78.1% vs. 71.4%), speciﬁcity
(88.5% vs. 69.4%) and overall accuracy (85% vs. 67.5%) than
FENa in differentiating renal from prerenal azotemia.
Those ﬁndings agree with Dewitte et al., in which FEurea
had better sensitivity (83% vs. 49%) and speciﬁcity (75% vs.
71%) than FENa in differentiating renal from prerenal azote-
mia [16]. But disagree with Pe´pin et al., in which 99 patients
with AKI showed that sensitivity and speciﬁcity of FEurea
were 79% and 33%, and concluded that FEurea could not
be used as an alternative tool in differentiating renal from pre-
renal azotemia as it lacks reasonable speciﬁcity [17]. The point
of difference from our study is that they mainly included pa-
tients with preexisting chronic kidney disease (40% of their
population) without correction of the FEurea values as de-
scribed by Nguyen et al., to compensate for the effect of the
chronic kidney disease on the FEurea value [18], while in our
study all patients with chronic kidney disease were excluded.
In our study FENa had a cutoff point of 1.1% for differen-
tiating renal from prerenal azotemia with reasonable sensitiv-
ity and speciﬁcity (71.4% and 69.4%, respectively). These
agree with Carvounis et al., who had a cutoff point of 1% with
high sensitivity and speciﬁcity (91% and 82%, respectively) [7].
However, the relatively lower sensitivity and speciﬁcity of our
FENa values can be attributed to; all our patients who had cir-
culatory shock with lactic acidosis and both dopamine and
noradrenaline infusion, which were additional factors that
led to increase in the false FENa values.
In our study, FEurea had a cutoff value at 34.1% for differ-
entiating renal from prerenal azotemia with a sensitivity and
speciﬁcity of 78.1% and 88.5%, respectively. This agrees with
Carvounis et al., which had a cutoff point of 35% with sensi-
tivity and speciﬁcity of 85%, 92%, respectively [7]. But dis-
agrees with Dewitte et al., who studied 47 ICU patients with
AKI, in which the best cutoff point of FEurea was 40% [16];
a level which is higher than ours. This can be explained as
the critically ill patients, as in Dewitte et al. study, commonly
have hypercatabolic disease, which may increase urea produc-
tion and excretion thereby increasing FEurea [16]. The point of
difference from our study is that, all our patients had circula-
tory shock with decreased tissue perfusion which affects the
catabolic state of the tissues making FEurea cutoff point in
our study slightly lower.
In our study, FEurea was almost not affected by the use of
frusemide diuretic therapy; sensitivity, speciﬁcity and overall
accuracy were 78%, 92% and 85% and 78%, 88% and85%, respectively without diuretics. The use of frusemide obvi-
ously affected FENa values and caused a decrease in the sen-
sitivity (64% vs. 71%), speciﬁcity (58% vs. 70%) and overall
accuracy (59% vs. 69%), respectively. Those ﬁndings agree
with Carvounis et al., in which the sensitivity of FEurea was
almost not affected by the use of diuretics (92% vs. 91%) while
that of FENa was markedly decreased with the use of diuretics
(92% vs. 52%). But disagree with Darmon et al., who con-
cluded that FEurea may be of little help in distinguishing renal
from prerenal azotemia in critically ill patients receiving diure-
tic therapy, however, they stated that few of their patients re-
ceived diuretics and poor performance of the urinary indices
was therefore related to low statistical power [19].
The mortality rate in our study was signiﬁcantly higher in
renal azotemia (50%) than in prerenal azotemia (19.2%),
(P< 0.05). This is supported by Vincent et al. and by Angus
et al., who found that the mortality rate was about 20% in
single organ failure, 40% in two organ failure, 70% in three
organ failure and reaching 90% in four organ failure [20,21].
The cutoff points of both FENa and FEurea as a predictor
of mortality were not statistically justiﬁed. This is explained as
all our patients had circulatory shock, and so patients with
mild renal impairment may die from their severe shock state,
and patients with severe renal affection may survive if their
shock could be rapidly corrected. This cutoff point calculation
is recommended only in patients with AKI without other or-
gan affections or shock that may affect the mortality.
Limitations
The limited number of our patients made it difﬁcult to perform
reliable statistical tests to explore the relations between both
FENa and FEurea vs. different types of shocks, which would
have added a lot of information to our study.
Conclusion
Although both fractional excretion of urea (FEurea) and frac-
tional excretion of sodium (FENa) are feasible, reproducible,
and inexpensive markers used in differentiating renal from pre-
renal azotemia, in our study FEurea showed higher sensitivity
and speciﬁcity than FENa, not only in differentiating renal
from prerenal azotemia in critically ill patients complicating
circulatory shock, but also its values were not affected by the
use of diuretics like FENa in the same group of patients.References
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